Adjunctive Therapy

Bezlotoxumab

Bezlotoxumab Dosing and PK

Bezlotoxumab (Zinplava)

• Recommended for:
  • Recurrent CDI episode – CDI within the past 6 months
  • Primary CDI with risk factors for recurrence:
    • ≥ 65 years old
    • Immunocompromised
    • Severe CDI on presentation
• Caution in heart failure
• Need to take logistics into account

• Wilcox MH, et al.
  • Patients receiving antibiotic treatment for primary or recurrent CDI had lower rates of recurrent infection than placebo
• Gerding DN, et al.
  • Patients with 3 or more risk factors had the greatest reduction of recurrent CDI

---

Summary